Prostate Cancer Clinical Trials

Showing 981-1000 of 2,150 trials

UNKNOWNEARLY Phase 1

Study of 177Lu-PSMA-0057 in Metastatic Prostate Cancer

NCT06050239

The purpose of this study is to evaluate the effectiveness and safety of 177Lu-PSMA-0057 in metastatic prostate cancer.

Metastatic Prostate Cancer

Nanjing First Hospital, Nanjing Medical University10 participantsStarted Mar 2023

Nanjing, Jiangsu, China

COMPLETEDPhase 1

A Phase 1 Dose Escalation and Expansion Study Of SHR7280 In Subjects With Hormone Sensitive Prostate Cancer

NCT04995042

This is an open-label, multicenter, dose escalation and expansion Phase 1 study of SHR7280 in adult patients with hormone sensitive prostate cancer.

Hormone Sensitive Prostate Cancer

Jiangsu HengRui Medicine Co., Ltd.12 participantsStarted Sep 2021

Qingdao, Shandong, China

COMPLETEDPhase 1/2

Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy

NCT01485861

This multicenter, international, Phase Ib/II trial consists of three stages: a Phase Ib, open-label stage in which the recommended Phase II dose was determined for ipataseritib administrated in combination with abiraterone and of apitolisib administrated in combination with abiraterone (this phase is no longer active), a Phase II, 3-arm, double-blind, randomized comparison of ipatasertib with abiraterone and prednisone/prednisolone versus placebo with abiraterone and prednisone/prednisolone and a safety single-arm, open-label cohort of ipatasertib 400 mg daily alone or in combination with prednisone/prednisolone or prednisone/prednisolone plus abiraterone.

Prostate Cancer

Genentech, Inc.298 participantsStarted Jan 2012

Scottsdale, Arizona, United States • San Francisco, California, United States • Fort Myers, Florida, United States +56 more locations

Study of 177Lu-PSMA-0057 in Metastatic Prostate Cancer

A Phase 1 Dose Escalation and Expansion Study Of SHR7280 In Subjects With Hormone Sensitive Prostate Cancer

Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy

Related Searches

Correlation Between Seminal Vesicle Size and Duration of Sexual Abstinence

Phase II Trial of Transdermal Estradiol for Hormone Refractory Prostate Cancer

Transperineal Versus Transrectal Prostate Biopsy

MRI in PROstate Cancer Diagnosis With Prior Risk Assessment

Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System

Non-systemic Treatment for Patients With Low-volume Metastatic Prostate Cancer

Quality of Life and Shared Decision Making in Prostate Cancer

Soccer Intervention in Prostate Cancer Survivors

A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer

Prostate Medication, Metabolism and Gut Microbiota

Inter-observer Variability in the Segmentation of Prostate Tumour Lesions Using Multiparametric MRI (VARIOP)

Hypofractionated Whole-Pelvis Radiotherapy (WPRT) vs Conventionally-Fractionated WPRT in Prostate Cancer

A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC

A Study of FT-7051 in Men With MCRPC

Diagnostic Performance of 18F-PSMA-1007 PET/CT in Suspected Prostate Cancer Patient

Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy